Literature DB >> 20686130

Reciprocal functional modulation of the activation of T lymphocytes and fibroblasts derived from human solid tumors.

Jennifer L Barnas1, Michelle R Simpson-Abelson, Stephen P Brooks, Raymond J Kelleher, Richard B Bankert.   

Abstract

Fibroblasts are a dominant cell type in most human solid tumors. The possibility that fibroblasts have the capacity to interact with and modulate the function of tumor-associated T lymphocytes makes them a potential therapeutic target. To address this question, primary cultures of fibroblasts derived from human lung tumors were established and cultured with T cells derived from the same tumor. The tumor fibroblasts significantly enhance the production of IFN-gamma and IL-17A by the tumor-associated T cells following a CD3/CD28-induced activation of the T cells. This enhancement was fibroblast cell dose-dependent and did not require direct contact between the two cell types. Tumor-associated fibroblast-conditioned media similarly enhanced both IFN-gamma and IL-17A in activated T cells, and this enhancement was significantly reduced by Abs to IL-6. Conditioned media derived from activated lymphocyte cultures significantly enhanced IL-6 production by tumor fibroblasts. A similar enhancement of IFN-gamma and IL-17A was observed when activated T cells from a normal donor were cultivated with skin fibroblasts derived from the same donor. These results establish that fibroblasts and autologous lymphocytes, whether derived from the tumor microenvironment or from nonmalignant tissues, have the capacity to reciprocally interact and modulate function. In contrast to other reports, fibroblasts are shown to have an immunostimulatory effect upon activated T lymphocytes. The ability of fibroblasts to enhance two T cell cytokines known to have an impact upon tumor progression suggests that fibroblasts play an important role in tumor pathogenesis that could be exploited therapeutically.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20686130     DOI: 10.4049/jimmunol.1000896

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

1.  A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells.

Authors:  Samantha Solito; Erika Falisi; Claudia Marcela Diaz-Montero; Andrea Doni; Laura Pinton; Antonio Rosato; Samuela Francescato; Giuseppe Basso; Paola Zanovello; Georgiana Onicescu; Elizabeth Garrett-Mayer; Alberto J Montero; Vincenzo Bronte; Susanna Mandruzzato
Journal:  Blood       Date:  2011-07-06       Impact factor: 22.113

Review 2.  The fibrotic tumor stroma.

Authors:  Mitsuo Yamauchi; Thomas H Barker; Don L Gibbons; Jonathan M Kurie
Journal:  J Clin Invest       Date:  2018-01-02       Impact factor: 14.808

3.  Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells.

Authors:  Y Deng; J Cheng; B Fu; W Liu; G Chen; Q Zhang; Y Yang
Journal:  Oncogene       Date:  2016-09-05       Impact factor: 9.867

Review 4.  Cancer-associated fibroblasts in digestive tumors.

Authors:  Lei Huang; A-Man Xu; Sha Liu; Wei Liu; Tuan-Jie Li
Journal:  World J Gastroenterol       Date:  2014-12-21       Impact factor: 5.742

Review 5.  Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy.

Authors:  Hong Jiang; Samarth Hegde; David G DeNardo
Journal:  Cancer Immunol Immunother       Date:  2017-04-27       Impact factor: 6.968

6.  Colorectal carcinoma-derived fibroblasts modulate natural killer cell phenotype and antitumor cytotoxicity.

Authors:  Tuanjie Li; Shuhong Yi; Wei Liu; Changchang Jia; Guoying Wang; Xuefeng Hua; Yan Tai; Qi Zhang; Guihua Chen
Journal:  Med Oncol       Date:  2013-07-20       Impact factor: 3.064

Review 7.  Molecular and clinical implementations of ovarian cancer mouse avatar models.

Authors:  Amira A Zayed; Sumithra J Mandrekar; Paul Haluska
Journal:  Chin Clin Oncol       Date:  2015-09

Review 8.  IL-17 in the Pathogenesis of Disease: Good Intentions Gone Awry.

Authors:  Saikat Majumder; Mandy J McGeachy
Journal:  Annu Rev Immunol       Date:  2021-02-12       Impact factor: 28.527

Review 9.  Cancer-associated fibroblasts: key determinants of tumor immunity and immunotherapy.

Authors:  Richard Barrett; Ellen Puré
Journal:  Curr Opin Immunol       Date:  2020-05-11       Impact factor: 7.486

Review 10.  Fibroblasts Influence the Efficacy, Resistance, and Future Use of Vaccines and Immunotherapy in Cancer Treatment.

Authors:  Bailee H Sliker; Paul M Campbell
Journal:  Vaccines (Basel)       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.